Stocks to Watch: JBS, Hims & Hers Health, Skydance, Rocket Lab

JBS reported lower Q3 profit, down 7.3% after-hours. Hims & Hers Health narrowed sales outlook, down 2.8%. Skydance plans $6B cost cuts, missed revenue estimates, down 2.1%. Rocket Lab posted wider-than-expected loss, down 6.6%.

Original reporting
Published Nov 10, 2026, 12:00 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 10, 2026, 12:33 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$JBS
Bearish
high confidence
Mentioned
$JBS · $HIMS · $RKLB
Relevance
4/10
AlphAI data visualization · based on morningstar.com
Decision brief

The 30-second read

$JBSBearishLow
01

Why it matters

Each company's earnings miss triggered an immediate share price decline, suggesting short‑term trading opportunities on the downside.

02

Market read

Earnings disappointments across these firms generate immediate negative sentiment and short‑term price pressure.

03

What to watch

Potential cost‑cutting measures and upcoming product launches may mitigate the downside.

Relevance 4/10Novelty 4/10Timing: after‑hours today

Background

The article provides a quick roundup of Q3 earnings and price reactions for four companies, highlighting profit shortfalls, guidance cuts, and larger-than-expected losses.

Company-level read

Ticker impact

$JBSBearishHigh confidence
Context

JBS reported lower Q3 profit and its stock fell 7.3% to $12.16 after-hours.

Expected impact

likely pressure as the market prices in weaker profit

Evidence & confidence

The profit shortfall and after‑hours sell‑off suggest short‑term downside.

$HIMSBearishHigh confidence
Context

Hims & Hers Health narrowed its sales outlook and posted an unexpected Q3 loss, with shares down 2.8% at $22.30.

Expected impact

likely pressure as investors digest the outlook reduction

Evidence & confidence

Guidance reduction and loss are fresh negative catalysts.

$RKLBBearishHigh confidence
Context

Rocket Lab posted a wider‑than‑expected Q3 loss, sending shares down 6.6% to $55.00.

Expected impact

likely pressure as the market reacts to the loss

Evidence & confidence

The larger loss and immediate price drop indicate short‑term downside.

Market effects

The earnings misses may weigh on the broader consumer health and aerospace sectors.

JBS's result could affect Latin American meat exporters; Rocket Lab's loss may influence U.S. small‑cap aerospace stocks.

Limited to investors tracking these specific companies; no broad macro impact.

Counterpoint

If the market overreacts to short‑term earnings misses, there could be a rebound on better‑than‑expected Q4 guidance.

Key entities

  • JBS

    Brazilian meat processor listed on NYSE (JBS).

  • Hims & Hers Health

    Telehealth and wellness company listed on NASDAQ (HIMS).

  • Rocket Lab

    Space launch provider listed on NASDAQ (RKLB).

Related articles

$AMZNMed

Amazon Lost 40 Leo Satellites as Launch Stays “Extremely Constrained.” That Widens SpaceX’s Lead

Amazon lost 40 satellites in a United Launch Alliance (ULA) Vulcan rocket failure, delaying its Leo satellite network. Amazon had planned 38 Vulcan launches for over 1,500 satellites, but ULA's investigation may cause further delays. Rocket Lab's CEO noted launch constraints, benefiting SpaceX, which launches its own Starlink satellites. Amazon must deploy 3,232 satellites by 2029 to retain FCC licenses, facing tight launch availability and competition from SpaceX.

$JBSMedAI 8/10

JBS Announces $542 Million Flora Acquisition To Enter Personal Care Market

JBS agreed to acquire Flora, a Brazilian consumer products company, for $542 million, including assumed debt. The deal, expected to close in December 2026, expands JBS into beauty and personal care. Flora generated $531 million in annual revenue. JBS will pay with Class A shares or Brazilian depositary receipts, expecting no change in net leverage. JBS also acquired Canal Rural, an agribusiness media company, for $11 million.

$RKLBMed

Rocket Lab, Viant, Lantronix Report Strong Revenue Gains

Rocket Lab (RKLB) reported Q3 revenue of $268M, up 70% YoY, and projects $270M-$290M for Q4. Viant (DSP) saw Q3 revenue rise 29% YoY, while Lantronix (LTRX) reported an 8% revenue increase. Karman (KRMN) raised its FY2026 revenue outlook to $755M-$760M. Ducommun (DCO) increased Q3 revenue by 6% and raised its full-year outlook. Indie Semiconductor (INDI) reported a 31% revenue increase. Clean Energy Fuels (CLNE) jumped 30% after better-than-expected Q3 results.

$RKLBMed

Selling Some Rocket Lab After Launch Record

Rocket Lab (RKLB) achieved its 100th Electron launch, deploying a satellite for iQPS. Goldman Sachs raised its target price to $68. ULA's Vulcan rocket failed, destroying Amazon's (AMZN) satellites, halting launches. Analysts adjusted targets for Ondas Inc (ONDS). Peloton (PTON) launched a cheaper treadmill, the Tread Flex, aiming to boost affordability.